» Articles » PMID: 31557974

Corticosteroids in Acute Lung Injury: The Dilemma Continues

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 Sep 28
PMID 31557974
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Acute lung injury (ALI) represents a serious heterogenous pulmonary disorder with high mortality. Despite improved understanding of the pathophysiology, the efficacy of standard therapies such as lung-protective mechanical ventilation, prone positioning and administration of neuromuscular blocking agents is limited. Recent studies have shown some benefits of corticosteroids (CS). Prolonged use of CS can shorten duration of mechanical ventilation, duration of hospitalization or improve oxygenation, probably because of a wide spectrum of potentially desired actions including anti-inflammatory, antioxidant, pulmonary vasodilator and anti-oedematous effects. However, the results from experimental vs. clinical studies as well as among the clinical trials are often controversial, probably due to differences in the designs of the trials. Thus, before the use of CS in ARDS can be definitively confirmed or refused, the additional studies should be carried on to determine the most appropriate dosing, timing and choice of CS and to analyse the potential risks of CS administration in various groups of patients with ARDS.

Citing Articles

Kirenol ameliorates endotoxin-induced acute lung injury by inhibiting the ERK and JNK phosphorylation-mediated NFκB pathway in mice.

Lin F, Chen S, Lin S, Tseng C, Tsai S, Kuan Y Inflammopharmacology. 2025; .

PMID: 40035943 DOI: 10.1007/s10787-025-01693-2.


Impact of the duration of corticosteroid treatment for postoperative acute lung injury following lung cancer surgery.

Zo S, Lee J, Jeon Y, Kim H, Jeon K J Thorac Dis. 2025; 17(1):220-230.

PMID: 39975726 PMC: 11833561. DOI: 10.21037/jtd-24-1295.


Wogonin attenuates inflammation and oxidative stress in acute lung injury via regulating PPARα, AKT, and NRF2.

Yang H, Hu Y, Cheng L, Xiong Y, Xu Y, Gao C Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39961805 DOI: 10.1007/s00210-025-03889-3.


Novel therapeutic effects of rifaximin in combination with methylprednisolone for LPS-induced ‎oxidative stress and inflammation in mice‎: ‎An study.

Al-Naimi M, Abu-Raghif A, Fawzi H Toxicol Rep. 2024; 13:101808.

PMID: 39640902 PMC: 11617758. DOI: 10.1016/j.toxrep.2024.101808.


Macrophage‑driven pathogenesis in acute lung injury/acute respiratory disease syndrome: Harnessing natural products for therapeutic interventions (Review).

Li J, Ma W, Tang Z, Li Y, Zheng R, Xie Y Mol Med Rep. 2024; 31(1).

PMID: 39513609 PMC: 11551695. DOI: 10.3892/mmr.2024.13381.


References
1.
Rogatsky I, Ivashkiv L . Glucocorticoid modulation of cytokine signaling. Tissue Antigens. 2006; 68(1):1-12. DOI: 10.1111/j.1399-0039.2006.00599.x. View

2.
Fang F, Zhang Y, Tang J, Lunsford L, Li T, Tang R . Association of Corticosteroid Treatment With Outcomes in Adult Patients With Sepsis: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018; 179(2):213-223. PMC: 6439648. DOI: 10.1001/jamainternmed.2018.5849. View

3.
Haran M, Schattner A, Kozak N, Mate A, Berrebi A, Shvidel L . Acute steroid myopathy: a highly overlooked entity. QJM. 2018; 111(5):307-311. DOI: 10.1093/qjmed/hcy031. View

4.
Meduri G, Headley A, Golden E, J Carson S, Umberger R, Kelso T . Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998; 280(2):159-65. DOI: 10.1001/jama.280.2.159. View

5.
Matute-Bello G, Frevert C, Martin T . Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008; 295(3):L379-99. PMC: 2536793. DOI: 10.1152/ajplung.00010.2008. View